Serosal Inflammation (pleural and Pericardial Effusions) Related to Tyrosine Kinase Inhibitors

Overview

Journal Target Oncol

Specialty Oncology

Date 2009 Apr 22

PMID 19381453

Citations 32

Authors

Kevin Kelly

Ronan Swords

Devalingam Mahalingam

Swaminathan Padmanabhan

Francis J Giles

Affiliations

Soon will be listed here.

Abstract

Tyrosine kinase inhibitors (TKIs) have dramatically changed the treatment of chronic myeloid leukemia (CML) and are increasingly used in other malignancies. Despite the apparent selectivity of these agents significant side effects can occur mainly due to off target kinase inhibition. Clinical consequences of serosal inflammation, including pleural and pericardial effusions, have emerged as a frequent adverse event associated with dasatinib while occurring much less frequently during imatinib and nilotinib therapy. The pathogenesis is uncertain but may involve inhibition of platelet derived growth factor or expansion of cytotoxic T and natural killer cells. The development of serosal inflammation with dasatinib poses a significant challenge to physicians, as it cannot be predicted, the time of onset is variable, and management frequently requires repeat invasive procedures.

Citing Articles

Pericarditis and Cardiac Tamponade in Patients Treated with First and Second Generation Bruton Tyrosine Kinase Inhibitors: An Underappreciated Risk.

Erblich T, Manisty C, Gribben J Case Rep Hematol. 2024; 2024:2312182.

PMID: 39015770 PMC: 11251797. DOI: 10.1155/2024/2312182.

Waldenström macroglobulinemia presenting as bilateral bloody pleural effusion: A case report.

Cen T, Zhang Q, Ying Y, Chen Z, Zhang X, Wu X Medicine (Baltimore). 2024; 103(24):e38406.

PMID: 38875392 PMC: 11175852. DOI: 10.1097/MD.0000000000038406.

A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.

Sun R, Ning Z, Qin H, Zhang W, Teng Y, Jin C Sci Rep. 2024; 14(1):9552.

PMID: 38664423 PMC: 11045761. DOI: 10.1038/s41598-024-55829-5.

Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP.

Kucukyurt S, Eskazan T, Ayer M, Kilickiran Avci B, Hatemi I, Eskazan A Pleura Peritoneum. 2024; 9(1):39-43.

PMID: 38558869 PMC: 10980979. DOI: 10.1515/pp-2023-0016.

Imatinib-Induced Pleuro-Pericardial Effusion and Atrial Fibrillation: An Unusual Side Effect Following the Treatment of a Rare Gastrointestinal Tumor.

Patel N, Jhaveri S, Hassen G, Avanthika C, Siddiq S Cureus. 2023; 15(4):e37727.

PMID: 37214033 PMC: 10191800. DOI: 10.7759/cureus.37727.

References

Druker B, Guilhot F, OBrien S, Gathmann I, Kantarjian H, Gattermann N . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23):2408-17. DOI: 10.1056/NEJMoa062867. View

Rix U, Hantschel O, Durnberger G, Remsing Rix L, Planyavsky M, Fernbach N . Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007; 110(12):4055-63. DOI: 10.1182/blood-2007-07-102061. View

Shah N, Nicoll J, Nagar B, Gorre M, Paquette R, Kuriyan J . Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002; 2(2):117-25. DOI: 10.1016/s1535-6108(02)00096-x. View

Hochhaus A, Kantarjian H, Baccarani M, Lipton J, Apperley J, Druker B . Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2006; 109(6):2303-9. DOI: 10.1182/blood-2006-09-047266. View

Berg L, Finkelstein L, Lucas J, Schwartzberg P . Tec family kinases in T lymphocyte development and function. Annu Rev Immunol. 2005; 23:549-600. DOI: 10.1146/annurev.immunol.22.012703.104743. View

Heldin C, Westermark B . Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999; 79(4):1283-316. DOI: 10.1152/physrev.1999.79.4.1283. View

Deininger M . Nilotinib. Clin Cancer Res. 2008; 14(13):4027-31. DOI: 10.1158/1078-0432.CCR-07-5015. View

Kawakami Y, Kitaura J, Hata D, Yao L, Kawakami T . Functions of Bruton's tyrosine kinase in mast and B cells. J Leukoc Biol. 1999; 65(3):286-90. DOI: 10.1002/jlb.65.3.286. View

Posadas E, Kwitkowski V, Kotz H, Espina V, Minasian L, Tchabo N . A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer. 2007; 110(2):309-17. DOI: 10.1002/cncr.22757. View

10.

Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D . Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004; 36(5):453-61. DOI: 10.1038/ng1343. View

11.

Matsuyama W, Mitsuyama H, Watanabe M, Shirahama Y, Higashimoto I, Osame M . Involvement of discoidin domain receptor 1 in the deterioration of pulmonary sarcoidosis. Am J Respir Cell Mol Biol. 2005; 33(6):565-73. DOI: 10.1165/rcmb.2005-0236OC. View

12.

Quintas-Cardama A, Kantarjian H, OBrien S, Borthakur G, Bruzzi J, Munden R . Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007; 25(25):3908-14. DOI: 10.1200/JCO.2007.12.0329. View

13.

Wilhelm S, Adnane L, Newell P, Villanueva A, Llovet J, Lynch M . Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008; 7(10):3129-40. DOI: 10.1158/1535-7163.MCT-08-0013. View

14.

Gorre M, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293(5531):876-80. DOI: 10.1126/science.1062538. View

15.

Hochhaus A, Baccarani M, Deininger M, Apperley J, Lipton J, Goldberg S . Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008; 22(6):1200-6. DOI: 10.1038/leu.2008.84. View

16.

Kantarjian H, Talpaz M, Giles F, OBrien S, Cortes J . New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006; 145(12):913-23. DOI: 10.7326/0003-4819-145-12-200612190-00008. View

17.

Shah N, Tran C, Lee F, Chen P, Norris D, Sawyers C . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004; 305(5682):399-401. DOI: 10.1126/science.1099480. View

18.

Sakamoto O, Suga M, Suda T, Ando M . Expression of discoidin domain receptor 1 tyrosine kinase on the human bronchial epithelium. Eur Respir J. 2001; 17(5):969-74. DOI: 10.1183/09031936.01.17509690. View

19.

Nam S, Kim D, Cheng J, Zhang S, Lee J, Buettner R . Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005; 65(20):9185-9. DOI: 10.1158/0008-5472.CAN-05-1731. View

20.

Weisberg E, Manley P, Breitenstein W, Bruggen J, Cowan-Jacob S, Ray A . Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005; 7(2):129-41. DOI: 10.1016/j.ccr.2005.01.007. View